

A photograph of two women, one with short brown hair and one with short grey hair, both smiling and laughing while cooking together outdoors. The woman with brown hair is in the foreground, and the woman with grey hair is behind her. They are both holding wooden spoons and appear to be stirring something in a pot. The background is a soft-focus outdoor setting.

DIGNITANA

Clinically superior scalp cooling

MAY 19 • 2022

**Solid growth trend
continues at 21 percent**



Q1 22

QUARTERLY REPORT

Solid growth trend continues at 21 percent

Financial highlights Q1 2022

- Net sales amounted to 15.9 MSEK (13.2), an increase of 21 percent over the same period in 2021.
- Operating result amounted to -6.1 MSEK (-7.1).
- Net result after financial items amounted to -6.5 MSEK (-7.7).
- Earnings per share were -0,10 SEK (-0,12).
- Cash Balance amounted to 11.3 MSEK (44.4).
- Average Daily Treatment Revenue (ADTR)* was 179 TSEK (130), an increase of 38 percent over the same period in 2021.

Significant events during the period

- The Board appointed Catarina Mård Löwenadler as Chief Executive Officer of Dignitana to begin on 20 May 2022.
- The company named Alf Christensson as Interim Chief Financial Officer and he assumed the role 1 March 2022.

Business highlights during the period

- On 9 March 2022 Dignitana Chief Executive Officer William Cronin addressed the Stockholm Corporate Finance Life Science Capital Markets Days, providing an update on the company's strategic growth and discussing current reimbursement initiatives.
- In early March Dignitana sponsored the More than Pink Walk in Orlando, Florida, continuing the partnership with Susan G Komen® we initiated in 2020 to increase awareness of scalp cooling.

Significant events after the period

- The company appointed Ulf Jönsson as Chief Financial Officer to begin 1 July 2022.



Key Figures

DIGNITANA GROUP	Q1 2022	Q1 2021	Full year 2021
Net sales, TSEK	15 864	13 165	57 073
Total revenues, TSEK	16 710	14 157	62 376
Net profit after financial items, TSEK	-6 508	-7 664	-43 076
Cash and bank balances, TSEK	11 311	44 366	14 501
Earnings per share before and after dilution, SEK	-0,10	-0,12	-0,66
Average Daily Treatment revenue, TSEK	179	130	147

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

Solid growth trend continues at 21 percent

The first quarter of 2022 represented yet another important and essential step forward for Dignitana as the fundamental picture for our company continues to improve. The pandemic has become less of a day-to-day concern for most with the necessity for getting “back to business” becoming clearer each day. Access to clinics is improving and in-person industry events are being scheduled again. The company has integrated the investments we made in our quality system and infrastructure to ensure we can accommodate the growth we anticipate in our global markets going forward. Tremendous steps have been made in the reimbursement area over the last year and, with several new initiatives undertaken, we believe the evolution towards the industry standard buy/bill model will allow us to expand both awareness of scalp cooling and clinic usage of our essential device and therapy option. Finally, our revenues continue to grow with net sales posting a 21 percent improvement over Q1 2021 and our all-important Average Daily Treatment Number (ADTR) improving 38 percent versus the same period one year ago.

The company has continued to stress improved device utilization rates over more rapid device installation rates. This strategy has enabled us to improve both device utilization rates as well as patient outcomes. This significant initiative was undertaken for two reasons. The first is to ensure that clinics that have installed DigniCap Delta are using the device on a regular basis so that patients obtain the best outcome possible. Consistent and regular usage of the device and application of the wrap ensures that the important nursing support element is both current and capable - and these factors directly impact patient success. Secondly, the logistics and spare parts challenges that have become endemic in the global marketplace are a potential concern that we monitor closely. To date our manufacturing partners and operations team have done an incredible job keeping the flow of devices and consumables on-line and our clinics supplied. We are taking a cautious approach to unit installations to ensure that we will have products available for the high-value, high-volume facilities our sales team continues to target. As the supply chain and logistical picture improves and our confidence that we can place and support every site we contract with in turn improves, we anticipate a more normalized and increased device placement schedule to resume.

The evolving and improving reimbursement environment necessary for scalp cooling to become Standard of Care in our important US market continues to be a very high priority initiative for Dignitana. The accomplishments of the previous 18 months include the original Current Procedural Terminology (CPT) code assignments and subsequent Centers for Medicare & Medicaid Services (CMS) rate

reassignments were enormously significant steps forward for making scalp cooling Standard of Care in the US. These all-important initial victories have become the foundation for all the continuing efforts to obtain maximum patient reimbursement we are undertaking. The US healthcare industry is a complex and multi-party insurance payer driven system that requires a significant, fact-based, and consistent approach to yield the desired and justifiable payment policies that patients deserve.

Finally, it has been my sincere honor and privilege to lead this company through the many challenges and accomplishments we have seen over the past 5 years. DigniCap Delta is the best scalp cooling product on the market and has enabled us to grow and gain market share through a generational business disruption that I hope none of us has to live through again. The pandemic-driven organizational improvements we have undertaken have served to make us a more efficient and nimble organization and these improvements will yield dividends well into the future. The Dignitana board and our committed team have every confidence that our new CEO, Catarina Mård Löwenadler, has the necessary skills, vision and energy to enable Dignitana to reach the full potential it has always had in front of it.



A handwritten signature in blue ink that reads "William Cronin".

William Cronin, CEO
Dignitana AB

The Company

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors

from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues. In 2019 Dignitana received CE Marking and FDA clearance for sales of DigniCap Delta, the next generation scalp cooling device, followed by approvals for the new model in Australia and Israel.

Business model


Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser. The Company produces the DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

Dignitana has two business models: in the United States devices are leased and the Company receives payments for each treatment. Outside the U.S. devices are sold to facilities and the company also receives revenue from service and maintenance agreements. The introduction of the DigniCap Delta system has added an additional revenue stream from consumables to both models with sales of the single-patient DigniCap Delta caps and patient kits.

While the pay-per-treatment model has been and continues to be the primary revenue driver for our US growth, the company is also taking significant steps towards ensuring we can seamlessly transition to the more traditional "buy/bill" model that healthcare providers utilize every day. The recent CMS rate assignment is the first step necessary for providers to finally make scalp cooling a billable service and thus be compensated for committing the resources

necessary to make scalp cooling therapy standard of care. The new "buy/bill" model is now being piloted at select locations. As this new model becomes more scalable and the reimbursement picture becomes clearer, we anticipate a full transition over to this standardized and widely accepted business model in the next 12-18 months.

For global markets that do not have the pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies. The single patient DigniCap Delta system is generating additional interest from the medical community with the global trend towards greater infection control standards.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 12 million incidences of solid tumors diagnosed annually, with more than 1,8 million diagnoses occurring in the U.S. each year. Dignitana estimates that 60 percent of these patients are on regimens compatible with DigniCap. Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with over 1,7 million cases of breast cancer diagnosed annually. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers.

To increase awareness of scalp cooling we work strategically with different organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship

of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this. In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this

treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per treatment fees, service and maintenance agreements, sales of individual caps and kit accessories. For the first quarter 2022 net sales amounted to 15 864 TSEK (13 165), an increase over the same period 2021 by 2 699 TSEK representing 21 percent growth.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased to health care providers and the Company generates revenues from the leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenues are generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements, as well as the sale of patient-related products and consumables.

The U.S. market continues to be the driver in the transition to DigniCap Delta and a revised business model. At the close of the quarter, there was an installed base of 398 devices. During the quarter the company has focused on a reallocation of lower utilized machines from some facilities to higher usage facilities to reach more patients and improve patient outcomes, thereby achieving higher growth.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In the first quarter 2022 net exchange rate effects amounted to 494 TSEK (986).

Operating Expenses and Operating Result

Operating expenses increased during the quarter compared to the same period last year by 1 018 TSEK and amounted to -13 740 TSEK (-12 722). Sequentially the operating expenses came down significantly as the focused activities with Quality and Regulatory Management came down to a more normalized level.

Travelling and marketing costs remained at moderate levels during the quarter. As the markets and society are starting to open up, we expect to see a somewhat increased activity level here going forward to support the continued sales expansion.

Depreciation and amortization in the Group amounted to -3 285 TSEK (-3 306) and remains largely unchanged.

The operating result after depreciation for the Group was for the first quarter -6 141 TSEK (-7 132).

Financial net

The financial net was -367 TSEK (-532), consisting mainly of debt-related interest.

Employees

The number of employees was at quarter-end 23 (27) employees.

Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was - 945 TSEK (-8 696), representing a significant improvement from previous quarters. Total cash flow for the period was -2 874 TSEK (-33 077). Cash and cash equivalents at the end of the quarter amounted to 11 311 TSEK (44 366).

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans combined with unutilized credit facilities are sufficient financial resources to cover working capital needs for the coming 12-month period.

CAPEX

Capex amounted to 217 TSEK (2 100) in the quarter.

DIGNITANA PARENT COMPANY

Revenues

Total revenues in the first quarter were 3 120 TSEK (9 992), of that other income was 617 TSEK (980) and is mainly attributable to exchange rate effects. The lower revenues in the quarter are primarily attributed to the timing of intercompany sales.

Operating Expenses and Operating Result

Operating expenses decreased during the quarter compared to the same period last year by 2 089 TSEK and amounted to -4 002 TSEK (-6 091).

The operating result was -5 370 TSEK (-2 139) and net result for the period was -5 344 TSEK (-2 445)

The Parent company expenses and revenues are highly influenced by the timing of intercompany charges without effects on the group level.

The share

Dignitana is listed on First North Growth Market since November 2011 after having been listed at Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap March 31	421 MSEK
Number of shareholders, approximately	2 563
Share price March 31	6,48
Number of shares traded during the quarter	1 355 074
Number of shares outstanding March 31	65 059 155
Registered share capital	6 505 916 SEK
Par value	0,1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and in February 2020 an extraordinary general meeting was held where a decision was taken to issue a maximum of 2 500 000 employee warrants to key employees of the Company. The period for exercising the employee stock warrants will run from 1 March

2023 to 31 March 2023. The employee warrants were granted gratuitously and yearly costs of 960 TSEK are booked continuously.

In December 2020, the Board of Directors decided on a directed share issue of initially SEK 41,294,000 and an additional SEK 33 706 000 after approval by an Extraordinary General Meeting held in January 2021. Through the issue, which comprised 10 000 000 shares at a subscription price of SEK 7.50, the Company received 75 000 TSEK before issue costs.



Largest Shareholders

31 MARCH 2022	HOLDINGS	PERCENT
AGARTHA AB *	17 000 000	26.13%
SWEDBANK ROBUR MICROCAP	5 000 000	7.69%
AVANZA PENSION	4 661 860	7.17%
CBLDN-UBS FINANCIAL SERVICES INC.	4 189 739	6.44%
HANDELSBANKEN MICROCAP SVERIGE	3 000 000	4.61%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA	2 612 835	4.02%
FE SMÅBOLAG SVERIGE	1 800 000	2.77%
TECHNOVOBIS AB	1 790 593	2.75%
POURSAMAD, AMIR	1 490 095	2.29%
RÜLF, SEMMY	1 015 058	1.56%
TOTAL	42 560 180	65.43%
OTHER SHAREHOLDERS	22 498 975	34.57%
TOTAL	65 059 155	100.00%

* Change of name from Adma AB to Agartna AB on 1 January 2022

Source: Euroclear

Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: Patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 has affected the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. The Company has therefore been impacted financially, although it is not possible to make a full assessment.

Risks related to the Russian invasion of Ukraine

The company's assessment is that the ongoing military conflict in Ukraine, should not have any immediate significant effect on the operations. Indirect effects such as increases in energy costs and transportation, increased lead time of components and general cost increases could have some impact on the operations but are deemed as manageable. If the conflict spreads to more territories, this assessment could change. USA is the groups primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2021 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements". Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc, and Dignitana Srl.

This interim report is prepared in accordance with Swedish GAAP, BFN 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2021.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2021 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 19 May 2022

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Board member and CEO

Richard Dilorio
Board member

Lina Karlsson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

This interim report has not
been audited by the Company auditors.

Income Statement – Dignitana Group, SEK

DIGNITANA GROUP	Q1 2022	Q1 2021	Full year 2021
Operating Income			
Net sales	15 864	13 165	57 073
Other operating income	846	992	5 303
Total Operating Income	16 710	14 157	62 376
Operating expense			
Goods for Resale	-5 826	-5 261	-20 711
Operating expense	-6 934	-6 043	-30 053
Personnel expense	-6 632	-6 605	-30 386
Depreciation and amortization of tangible and intangible assets	-3 285	-3 306	-12 737
Other operating expenses	-174	-74	-10 043
	-22 851	-21 289	-103 930
Operating profit (loss)	-6 141	-7 132	-41 554
Result from financial investments			
Other Interest income and similar items	70	56	118
Interest expenses and similar items	-437	-588	-1 640
	-367	-532	-1 522
Profit after financial items	-6 508	-7 664	-43 076
Profit before tax	-6 508	-7 664	-43 076
Tax on profit for the period	0	0	-10
Results for the Period	-6 508	-7 664	-43 086
Average number of shares before and after dilution	65 059 155	62 812 113	65 059 155
Earnings per share before and after dilution, SEK	-0,10	-0,12	-0,66

Balance Sheet – Dignitana Group, SEK

DIGNITANA GROUP	Q1 2022	Q1 2021	Full year 2021
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development	10 072	14 655	11 189
	10 072	14 655	11 189
<u>Tangible assets</u>			
Equipment, tools and installations	181	251	187
Machinery and other technical facilities	28 105	27 639	30 104
	28 286	27 890	30 291
Total Fixed Assets	38 358	42 546	41 480
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	7 275	6 703	7 120
	7 275	6 703	7 120
<u>Current Receivables</u>			
Accounts Receivable	5 598	6 293	5 103
Current Tax Assets	72	71	66
Other Current Receivables	1 095	1 024	862
Prepaid expenses and accrued income	1 446	1 428	2 222
	8 211	8 817	8 253
Cash and Bank Balances	11 311	44 366	14 501
Total Current Assets	26 797	59 886	29 874
Total Assets	65 155	102 431	71 354
EQUITY AND LIABILITIES			
Equity			
Share Capital	6 506	6 506	6 506
Unregistered share capital	0	0	0
Ongoing new issue	0	0	0
Other contributed capital	222 692	222 692	222 692
Other equity including profit for the year	-205 243	-161 460	-198 012
Total Equity	23 955	67 738	31 186
Provisions			
Other provisions	6	18	69
	6	18	69
Long Term Liabilities			
Other long term liabilities	14 386	396	15 828
Total Long Term Liabilities	14 386	396	15 828
Current Liabilities			
Liabilities to credit institutions	8 082	7 493	7 762
Accounts payable	9 728	12 960	6 234
Other current liabilities	593	4 133	761
Accrued expenses and deferred income	8 405	9 693	9 514
Total current liabilities	26 808	34 279	24 271
Total liabilities	41 194	34 675	40 099
Total Equity and Liabilities	65 155	102 431	71 354

Changes in Equity – Dignitana Group, SEK

	Sharecapital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2021	6 506	222 692	-151 562	77 636
Net loss for the year			-43 086	-43 086
Option program 2021			960	960
Change in translation difference relating to subsidiaries			-4 324	-4 324
Closing equity on 12/31/2021	6 506	222 692	-198 012	31 186
Net loss for the period			-6 508	-6 508
Option program 2022			270	270
Change in translation difference relating to subsidiaries			-993	-993
Closing equity on 3/31/2022	6 506	222 692	-205 243	23 955

Statement of Cash Flows – Dignitana Group, SEK

DIGNITANA GROUP	Q1 2022	Q1 2021	Full year 2021
Operating Activities			
Profit after financial investments	-6 508	-7 664	-43 076
Adjustments for items not affecting cash flows, etc	3 975	3 097	12 288
Tax paid	-8	-10	-80
Cash flow from operating activities before changes in working capital	-2 541	-4 577	-30 868
Cash flow from changes in working capital			
Change in inventories	-110	848	-467
Change in other current receivables	159	-338	422
Change in other current liabilities	1 547	-4 629	-12 960
Cash flows from operating activities	-945	-8 696	-43 873
Investing activities			
Investments in intangible assets	0	0	0
Proceeds from sale of intangible assets	0	0	0
Investments in tangible assets	-217	-2 100	-10 556
Cash flows from investing activities	-217	-2 100	-10 556
Financing activities			
New share issue	0	0	0
Issue expenses	0	0	0
Liabilities to credit institutions	0	0	0
Options issued	0	0	0
New loans	0	0	0
Repaid loans	0	-20 000	-20 000
Changes in long and short term liabilities	-1 712	-2 280	12 679
Cash flow from financial activities	-1 712	-22 280	-7 321
Cash flow for the period	-2 874	-33 077	-61 750
Cash and cash equivalents at beginning of period	14 501	78 770	78 770
Exchange-rate differences in cash and cash equivalents	-316	-1 327	-2 519
Cash and cash equivalents at end of period	11 311	44 366	14 501

Income Statement – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	Q1 2022	Q1 2021	Full year 2021
Operating Income			
Net sales	2 503	9 012	37 743
Other operating income	617	980	1 940
Total Operating Income	3 120	9 992	39 683
Operating expense			
Goods for Resale	-1 234	-2 792	-7 179
Operating expense	-2 519	-2 525	-41 512
Personnel expense	-1 354	-3 566	-5 367
Depreciation and amortization of tangible and intangible assets	-3 254	-3 248	-12 517
Other operating expenses	-129	0	-3 430
	-8 490	-12 131	-70 005
Operating profit (loss)	-5 370	-2 139	-30 322
Result from financial investments			
Other Interest income and similar items	70	56	118
Interest expenses and similar items	-44	-362	-473
	26	-306	-355
Profit after financial items	-5 344	-2 445	-30 677
Profit before tax	-5 344	-2 445	-30 677
Tax on profit for the period	0	0	0
Results for the Period	-5 344	-2 445	-30 677

Balance Sheet – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	Q1 2022	Q1 2021	Full year 2021
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development	10 048	14 629	11 165
	10 048	14 629	11 165
<u>Tangible assets</u>			
Equipment, tools and installations	0	0	0
Machinery and other technical facilities	155	27 639	30 104
	155	27 639	30 104
<u>Financial assets</u>			
Participations in group companies	522	522	522
Receivable from group companies	463	436	452
	985	958	974
Total Fixed Assets	11 188	43 226	42 243
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	5 328	5 038	5 289
	5 328	5 038	5 289
<u>Current Receivables</u>			
Accounts Receivable	1 472	1 945	1 927
Receivables from group companies	56 646	30 491	26 992
Current Tax Assets	72	71	117
Other Current Receivables	1 014	918	772
Prepaid expenses and accrued income	690	741	854
	59 894	34 166	30 662
Cash and Bank Balances	4 828	39 958	9 239
Total Current Assets	70 050	79 162	45 190
Total Assets	81 238	122 389	87 433
EQUITY AND LIABILITIES			
Equity			
<u>Restricted equity</u>			
Share Capital	6 506	6 506	6 506
Unregistered share capital	0	0	0
Fund for development expenses	10 048	14 514	11 165
	16 554	21 020	17 671
<u>Non-restricted equity</u>			
Share premium reserves	222 692	222 692	222 692
Other non-restricted equity	-159 002	-132 792	-129 442
Results for the period	-5 344	-2 445	-30 677
	58 346	87 455	62 573
Total Equity	74 900	108 476	80 244
Current Liabilities			
Accounts payable	1 532	9 481	2 124
Current payable to group company	0	0	0
Other current liabilities	95	162	129
Accrued expenses and deferred income	4 711	4 270	4 936
Total current liabilities	6 338	13 913	7 189
Total liabilities	6 338	13 913	7 189
Total Equity and Liabilities	81 238	122 389	87 433

Financial calendar

18 August 2022	Q2 Report
17 November 2022	Q3 report
16 February 2023	2022 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.se

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se